利用18F-氟乙基酪氨酸(FET)正电子发射断层成像(PET)界定疑似非强化肿瘤以制定胶质母细胞瘤放疗计划
本研究回顾性分析26例胶质母细胞瘤(GBM)伴疑似非强化肿瘤患者,术后行FET-PET,比较基于MRI的临床靶体积(CTVFLAIR、CTVSx)与基于FET-PET的生物肿瘤体积(BTVFLAIR、BTVSx)。FET-PET使靶体积平均增加26.8%和20.6%(均P<.0001)。作者认为FET-PET可能有助于改善GBM勾画并降低地理遗漏风险。
要点
- FET-PET使CTVFLAIR至BTVFLAIR平均体积增加26.8%,CTVSx至BTVSx增加20.6%,差异均P<.0001。
- 24例可评估患者中,6例(25%)放疗前FET高摄取区在放疗野内出现局灶性钆增强。
- 作者认为FET-PET可能有助于改善疑似非强化GBM的勾画并降低地理遗漏风险。
核心结论
- 作者认为,FET-PET可能有助于改善存在疑似非强化成分的GBM的勾画,并可能改善放疗靶区界定、降低潜在地理遗漏风险。
研究设计与样本
- 回顾性从本院数据库识别26例GBM且增强MRI显示疑似非强化肿瘤区域的患者,术后放疗前接受FET-PET。
- 基于术前和术后MRI创建两个临床靶体积:CTVFLAIR(基于FLAIR序列)和CTVSx(基于增强序列并外扩手术腔)。
- 基于FET-PET创建生物肿瘤体积BTVFLAIR和BTVSx,纳入FET高摄取区域。
- 使用Wilcoxon符号秩检验比较CTV与相应BTV的体积,并分析加入FET后的体积增加。
- 放疗后1个月和3个月MRI观察既往非强化肿瘤内或FET高摄取区内是否出现局灶性钆增强。
主要发现
- 26例患者中24例显示可测量的FET摄取。
- CTVFLAIR、CTVSx、BTVFLAIR、BTVSx的中位体积分别为57.1 mL(范围1.1-217.4)、83.6 mL(范围27.2-275.8)、62.8 mL(范围1.1-307.3)、94.7 mL(范围27.2-285.5)。
- 使用FET-PET后,CTVFLAIR至BTVFLAIR平均体积增加26.8%,CTVSx至BTVSx平均增加20.6%。
- Wilcoxon符号秩检验显示CTVFLAIR与BTVFLAIR之间(P<.0001)及CTVSx与BTVSx之间(P<.0001)体积变化有统计学显著差异。
- 24例放疗前FET高摄取患者中,6例(25%)在放疗野内出现局灶性钆增强。
关键数值与推荐
- CTVFLAIR中位体积57.1 mL(范围1.1-217.4),CTVSx中位体积83.6 mL(范围27.2-275.8)。
- BTVFLAIR中位体积62.8 mL(范围1.1-307.3),BTVSx中位体积94.7 mL(范围27.2-285.5)。
- CTVFLAIR至BTVFLAIR平均体积增加26.8%(P<.0001),CTVSx至BTVSx平均增加20.6%(P<.0001)。
- 24例FET高摄取患者中6例(25%)放疗野内出现局灶性钆增强。
临床怎么用
- 作者认为,FET-PET可能有助于改善存在疑似非强化成分的GBM的勾画,并可能降低潜在地理遗漏风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The authors sought to evaluate the impact of 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) on radiation therapy planning for patients diagnosed with glioblastoma (GBM) and the presence of suspected nonenhancing tumors compared with standard magnetic resonance imaging (MRI). METHODS AND MATERIALS: Patients with GBM and contrast-enhanced MRI scans showing regions suspicious of nonenhancing tumor underwent postoperative FET-PET before commencing radiation therapy. Two clinical target volumes (CTVs) were created using pre- and postoperative MRI: MRI fluid-attenuated inversion recovery (FLAIR) sequences (CTVFLAIR) and MRI contrast sequences with an expansion on the surgical cavity (CTVSx). FET-PET was used to create biological tumor volumes (BTVs) by encompassing FET-avid regions, forming BTVFLAIR and BTVSx. Volumetric analyses were conducted between CTVs and respective BTVs using Wilcoxon signed-rank tests. The volume increase with addition of FET was analyzed with respect to BTVFLAIR and BTVSx. Presence of focal gadolinium contrast enhancement within previously nonenhancing tumor or within the FET-avid region was noted on MRI scans at 1 and 3 months after radiation therapy. RESULTS: Twenty-six patients were identified retrospectively from our database, of whom 24 had demonstrable FET uptake. The median CTVFLAIR, CTVSx, BTVFLAIR, and BTVSx were 57.1 mL (range, 1.1-217.4), 83.6 mL (range, 27.2-275.8), 62.8 mL (range, 1.1-307.3), and 94.7 mL (range, 27.2-285.5), respectively. When FET-PET was used, there was a mean increase in volume of 26.8% from CTVFLAIR to BTVFLAIR and 20.6% from CTVSx to BTVSx. A statistically significant difference was noted on Wilcoxon signed-rank test when assessing volumetric change between CTVFLAIR and BTVFLAIR (P < .0001) and CTVSx and BTVSx (P < .0001). Six of 24 patients (25%) with FET avidity before radiation therapy showed focal gadolinium enhancement within the radiation therapy portal. CONCLUSIONS: FET-PET may help improve delineation of GBM in cases with a suspected nonenhancing component. This may result in improved radiation therapy target delineation and reduce the risk of potential geographical miss. SUMMARY: We investigated the impact of 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) on radiation therapy planning for patients diagnosed with glioblastoma (GBM) and a suspected nonenhancing tumor compared with standard magnetic resonance imaging. We performed volumetric analyses between clinical target volumes and respective biological target volumes using Wilcoxon signed-rank tests. FET-PET may help improve delineation of GBM in cases with a suspected nonenhancing component and reduce the risk of potential geographical miss.
引用
- Hayes AR, Jayamanne D, Hsiao E, et al. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018. PMID: 29730279. doi:10.1016/j.prro.2018.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。